Cookie Policy

This site uses cookies to store information on your computer.

I accept the terms and conditions
Befehle des Menübands überspringen
Zum Hauptinhalt wechseln

LeukoGuard BC2

Pall Leukocyte Reduction Blood Cardioplegia Filter

Features and Benefits
The Pall Leukocyte Reduction Blood Cardioplegia Filter combines leukocyte reduction filtration media with a conventional 40 µm micro-emboli removal screen. The new low volume housing (95 mL) and improved media pleating technique allows easy application in modern blood cardioplegia systems.
● Reduces blood cardioplegia of circulating leukocytes, specifically activated neutrophils, which have been implicated as a major cause of myocardial reperfusion injury. (note: the removal efficiency will depend on total volume of blood cardioplegia delivered and the conditions which the blood cardioplegia is administered (i.e. flow, temperature, haemodilution etc).
● Incorporates a 40 µm screen capable of retaining gaseous and particulate microemboli.
● Designed to handle flow rates up to 350 mL/min, for a 3 litre
throughput, over a wide range of cardioplegia administration practices.

* For clinical data please see clinical update or contact your Pall representative.









LeukoGuard BC2 Flyer Product Info/LeukoGuard BC2 Flyer EC89.pdfLeukoGuard BC2 Flyer 09.07.2015 22:00:00{FAF101DE-D6E7-490B-A5D7-5A4ACB1A5508}HayabusaArticleDocument77054ba1-476b-4af3-b914-9a049e0b9ba8

See Also

Did you not find the product you were looking for ?